Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 2/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.30 |
| ▸ | TNKS | O95271 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31093701 | 0.86 | CYP4F2 (0.37) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL30392077 | 0.85 | CYP4F2 (0.38) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL23043800 | 0.85 | CYP4F2 (0.38) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL30858862 | 0.84 | RXRA (0.37) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL20581028 | 0.84 | RXRA (0.37) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL31015405 | 0.82 | PDE1B (0.36) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL15229935 | 0.82 | RXRA (0.35) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL30797632 | 0.82 | CREBBP (0.35) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL138511 | 0.81 | RXRA (0.37) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL25795327 | 0.80 | RXRA (0.40) | RXRARXRBRXRGATRCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060961-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-03-05 | — | — | US | disclosed |
| EP-4581024-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | Jazz Pharmaceuticals Ireland Limited (IE) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024047135-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060961-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | KRAS, NRAS, HRAS | RXRA 2971/4885RXRB 2727/4885RXRG 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.